Newsmeme!
Discover News you didn't know existed
Anticoagulants
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
For Good Health, Don't Ignore an Irregular Heartbeat
Published September 5, 2008, 10:50 pm, Carteret County News-Times
(ARA) - Does your heart ever beat irregularly? Perhaps you get an occasional flutter, or your heart races or beats slow for a short amount of time. For most people, these occasional, irregular heartbeats are common and harmless.
Results Of The APPRAISE-I Dose Guiding Trial
Published September 4, 2008, 6:09 am, Medical News Today
While the results of the study did not show a statistically significant difference in ischemic events among any of the four doses of apixaban evaluated, trends emerged that support further study, according to researchers at the Duke Clinical Research Institute. Apixaban targets the activity of Factor Xa, one of several enzymes involved in process of blood coagulation.
Safety Of Antithrombotic Treatment In Acute Coronary Syndromes
Published September 4, 2008, 5:11 am, Medical News Today
The management of acute coronary syndromes (with or without ST segment elevation) requires the use of anticoagulants, antiplatelet agents (aspirin, clopidogrel and/or glycoprotein (GP) IIb/IIIa inhibitors), beta-blockers, thrombolytics in some cases, and revascularization / reperfusion.
Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced The Risk Of Stroke In Patients With ...
Published September 4, 2008, 3:10 am, Medical News Today
This Analysis Showed That Multaq(R) (Dronedarone) Decreased the Risk of Stroke by 34% in Patients With Atrial Fibrillation or Atrial Flutter Already Adequately Treated by Antithrombotic Therapy The results of a post-hoc analysis of the data from the ATHENA study were presented
APPRAISE-1 study of apixaban provides encouraging results
Published September 3, 2008, 8:52 pm, PharmaBiz
Bristol-Myers Squibb Company and Pfizer Inc announced the results of a phase-2 dose-ranging study (APPRAISE-1) involving the investigational compound apixaban in patients with acute coronary syndrome (ACS, commonly known as heart attack or severe chest pain).
Further Analysis From The ATHENA Study Showed That Multaq® (dronedarone) Reduced The Risk Of Stroke In Patients With ...
Published September 3, 2008, 6:10 am, Medical News Today
The results of a post-hoc analysis of the data from the ATHENA study were presented today at the clinical trial update session of the European Society of Cardiology congress 2008, in Munich, Germany.
Pfizer reports tests for coronary drug are 'encouraging'
Published September 3, 2008, 4:03 am, New London Day
Apixaban, a new compound in midstage development by Pfizer Inc. and Bristol-Myers Squibb Co., showed “encouraging trends” in its effect on coronary patients, though the
My Pharmiweb.com
Published September 3, 2008, 1:24 am, PharmiWeb
Munich, Germany- Sept 3rd, 2008 The results of a post-hoc analysis of the data from the ATHENA study were presented today at the clinical trial update session of the European Society of Cardiology congress 2008, in Munich, Germany.
Further Analysis from ATHENA Study Showed That Multaq(R) (Dronedarone) Reduced the Risk of Stroke in Patients With ...
Published September 3, 2008, 12:17 am, Thaipr.net
- This Analysis Showed That Multaq(R) (dronedarone) Decreased the Risk of Stroke by 34% in Patients With Atrial Fibrillation or Atrial Flutter Already Adequately Treated by Antithrombotic Therapy
Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With ...
Published September 2, 2008, 11:30 pm, PR Newswire via Yahoo! Finance
-
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |